Sialic acid-modified dexamethasone lipid calcium phosphate gel core

nanoparticles for target treatment of kidney injury

Hongbing Liu^a, Hui Zhang^a, Na Yin^a, Ying Zhang^a, Jingxin Gou^a, Tian Yin^b, Haibing He^a, Hong Ding^{c, *}, Yu Zhang^{a, *}, Xing Tang^a

^a Department of Pharmaceutics, Shenyang Pharmaceutical University, Wen Hua Road No.103, Shenyang, China

^b School of Functional Food and Wine, Shenyang Pharmaceutical University, Wen Hua Road No.103, Shenyang, China

^c Department of Nephrology, The Forth Affiliated Hospital, China Medical University, Chongshan

East Road No.4, Shenyang, China

*Corresponding author:

Professor Yu Zhang

Tel: +86 24 23986343; Fax: +86 24 23911736. E-mail address: pharmzy@163.com

Dr. Hong Ding

Tel: +86-18900912198; E-mail: dinghong9209@126.com

1. Cell viability assay



Fig. S1 *In vitro* cell viability experiments with free drugs, NPs and SA-NPs. Three samples were repeated for each group.

2. The expression of E-selectin receptors



Fig.S2 Immunofluorescence imaging of non-activated (A, B) and LPS-activated (C, D) HUVEC cells after 4 hours incubation with Cy5-loaded NPs (A, C) and SA-NPs (B, D). And an enlarged view of the merged image of confocal imaging of the cell nucleus (blue), nanoparticles (red), and E-selectin receptor (green).

3. In vivo pharmacokinetic study



Fig.S3 Mean plasma concentration-time curves of Dex after intravenous Dsp, NPs and SA-NPs with a dose of

1.5mg/kg (n=6).

4. Biodistribution of NPs and SA-NPs



Fig.S4 The AUC of kidney average radiant efficiency-time of different groups in the biodistribution experiment.